Intravenous immune globulin

FDA

• Bone marrow transplant (to prevent graft vs host disease)
• Primary immunoglobulin deficiencies (hypogammaglobulinemia)
• Idiopathic thrombocytopenic purpura (ITP)
• Prevention of bacterial infections in HIV-infected children who are not receiving prophylaxis (FDA approved but generally not recommended)
• Kawasaki disease
• VZV post-exposure prophylaxis (if Varicella-Zoster immune globulin is not available)

NON-FDA APPROVED USES

• Autoimmune hemolytic anemias
• Pure red cell aplasia
• Guillain-Barre syndrome
• Steroid resistant dermatomyositis
• Polymyositis
• Multifocal motor neuropathy
• Multiple myeloma
• Immune-mediated neutropenia
• Post-transfusion purpura
• Neonatal alloimmune thrombocytopenia
• Solid-organ transplant
• Myasthenia gravis
• Multiple sclerosis
• Systemic lupus diseases
• Systemic vascular syndrome and vasculitis
• Refractory seizures
• Chronic inflammatory demyelinating polyneuropathy
• Stiff person syndrome
• Paraneoplastic syndrome
• Thrombocytopenia refractory to platelet transfusion
• Immune deficiencies and immune regulatory disorders

Infectious Diseases Use

• Group A Strep TSS

• Measles post-exposure prophylaxis
• Adjective therapy for RSV in the severely immunocompromised host (e.g. BMT)
• Severe C. difficile-associated colitis
• Anemia due to parvovirus B19 infection
• CMV infections
• BK virus nephropathy[1]